NCT05273918

Brief Summary

This is a multi-center, prospective, randomized, open-label, controlled trial with two parallel arms and blinded endpoint assessment. It aims yo compare the 6-month efficacy of a group CBT program versus body-mediated intervention (meditation) children (7-13 years) with ADHD-associated FASD and emotional dysregulation via a measurement of the Aggressive Behaviors subscale score of the Dysregulation Profile subset of the CBCL scale.

Trial Health

53
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
29mo left

Started Jan 2023

Longer than P75 for not_applicable

Geographic Reach
2 countries

3 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Jan 2023Oct 2028

First Submitted

Initial submission to the registry

March 1, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 10, 2022

Completed
10 months until next milestone

Study Start

First participant enrolled

January 1, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
5.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2028

Expected
Last Updated

October 2, 2023

Status Verified

September 1, 2023

Enrollment Period

6 months

First QC Date

March 1, 2022

Last Update Submit

September 28, 2023

Conditions

Keywords

FASDADHD

Outcome Measures

Primary Outcomes (1)

  • effectiveness of cognitive behavioral therapy program

    score on Child Behavior Check List (CBCL) scale. Minimum value = 50 (normal) and maximal value = 100 (pathologic). Score between 50 and 65 is mormal and score between 70 and 100 is pathologic and needs patients medical care.

    7 months after inclusion

Study Arms (2)

Therapy cognitivo-comportmental

EXPERIMENTAL

Each child will participate in a structured cognitive behavioral therapy program entitled "better manage your anger and frustration". 15 workshops is planned.

Other: cognitivo-comportmental therapy

Body mediation

ACTIVE COMPARATOR

Each child will participate in sports, artistic or fun activities involving the body (physical, emotional and communicative dimensions)

Other: body mediation

Interventions

15 workshops once a week during 90 minutes

Therapy cognitivo-comportmental

15 workshops once a week during 90 minutes

Body mediation

Eligibility Criteria

Age7 Years - 13 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • child with fetal alcohol spectrum disorder
  • child with attention deficit disorder with / without hyperactivity
  • child with a score upper than or equal to 180 points on the "Aggressive behavior", "Anxiety / Depression" and "Concentration problems" subscales of the CBCL
  • child followed in La Reunion, Montpellier or Bordeaux University Hospital
  • child whose parents are affiliated with social security
  • child who accepts to participate and whose parents have given their consent

You may not qualify if:

  • non-french speaking child or parents / non-creole speaking child or parents
  • child who already participate to CBT or body mediation groups

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

CHU de Bordeaux

Bordeaux, 33076, France

Location

CHU de Montpellier - Hôpital Saint Eloi

Montpellier, 34070, France

Location

CHU de La Réunion

Saint-Pierre, 97448, Reunion

Location

MeSH Terms

Conditions

Fetal Alcohol Spectrum DisordersAttention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Fetal DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesAlcohol-Induced DisordersAlcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersAttention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Study Officials

  • Michel SPODENKIEWICZ, MD

    CHU de La Réunion

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2022

First Posted

March 10, 2022

Study Start

January 1, 2023

Primary Completion

July 1, 2023

Study Completion (Estimated)

October 1, 2028

Last Updated

October 2, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations